SHANGHAI, Dec. 28, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announced that it has submitted two separate Investigational New Drug (IND) applications to the National Medical Products...
Hence then, the article about carsgen submits dual ind applications for allogeneic bcma car t product ct0596 was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( CARsgen Submits Dual IND Applications for Allogeneic BCMA CAR-T Product CT0596 )
Also on site :
- Chainlink and Multinational Banking Consortia Launch Project Pangea To Develop T+0 Settlement Framework for International FX Markets
- The 1999 Movie That Changed Horror Forever Is Returning to Theaters — and It Has a Premiere Date
- This New Ultra-Luxury Hotel Lets Travelers Stay Inside One of the World's Oldest UNESCO Biosphere Reserves